| Time at risk (person-years) | Incidence rate (per 1000 person-years) | Unadjusted HR (95 % CI) | Adjusted HR* (95 % CI) | p value |
---|---|---|---|---|---|
MACEs | |||||
Antidiabetic drug (ref. = DPP4i) | 28,508 | 39.56 | – | – | – |
No antidiabetic drug | 101,166 | 62.02 | 1.52 (1.39, 1.65) | 1.31 (1.20, 1.43) | <0.0001 |
Sulfonylureas | 110,618 | 35.99 | 0.89 (0.81, 0.96) | 0.96 (0.88, 1.05) | 0.3942 |
Acarbose | 22,800 | 48.37 | 1.20 (1.08, 1.33) | 1.07 (0.96, 1.18) | 0.2098 |
Meglitinides | 13,103 | 102.49 | 2.52 (2.27, 2.78) | 1.68 (1.52, 1.86) | <0.0001 |
Insulin | 9632 | 206.06 | 5.08 (4.60, 5.61) | 3.73 (3.35, 4.14) | <0.0001 |
Metformin | 172,813 | 30.87 | 0.76 (0.69, 0.82) | 0.87 (0.79, 0.94) | 0.0009 |
Pioglitazone | 4678 | 24.15 | 0.59 (0.47, 0.73) | 0.70 (0.56, 0.86) | 0.0011 |
Rosiglitazone | 504 | 35.64 | 0.78 (0.48, 1.23) | 0.89 (0.55, 1.42) | 0.6296 |
Ischemic stroke | |||||
Antidiabetic drug (ref. = DPP4i) | 28,508 | 20.69 | – | – | – |
No antidiabetic drug | 101,166 | 35.83 | 1.68 (1.49, 1.89) | 1.42 (1.26, 1.60) | <0.0001 |
Sulfonylureas | 110,618 | 21.95 | 1.03 (0.92, 1.16) | 1.06 (0.94, 1.19) | 0.3465 |
Acarbose | 22,800 | 26.18 | 1.24 (1.08, 1.43) | 1.09 (0.94, 1.25) | 0.2432 |
Meglitinides | 13,103 | 50.98 | 2.39 (2.07, 2.75) | 1.58 (1.37, 1.81) | <0.0001 |
Insulin | 9632 | 111.07 | 5.23 (4.58, 5.97) | 3.99 (3.47, 4.56) | <0.0001 |
Metformin | 172,813 | 20.61 | 0.97 (0.86, 1.08) | 1.03 (0.92, 1.15) | 0.5630 |
Pioglitazone | 4678 | 13.25 | 0.62 (0.47, 0.82) | 0.71 (0.53, 0.94) | 0.0166 |
Rosiglitazone | 504 | 23.76 | 0.99 (0.55, 1.75) | 1.06 (0.59, 1.87) | 0.8551 |
Myocardial infarction | |||||
Antidiabetic drug (ref. = DPP4i) | 28,508 | 5.19 | – | – | – |
No antidiabetic drug | 101,166 | 7.01 | 1.47 (1.20, 1.80) | 1.45 (1.18, 1.78) | 0.0003 |
Sulfonylureas | 110,618 | 4.21 | 0.83 (0.68, 1.01) | 0.98 (0.80, 1.78) | 0.8257 |
Acarbose | 22,800 | 5.08 | 1.00 (0.77, 1.29) | 0.98 (0.75, 1.27) | 0.8993 |
Meglitinides | 13,103 | 9.53 | 1.89 (1.49, 2.39) | 1.49 (1.17, 1.90) | 0.0011 |
Insulin | 9632 | 17.64 | 3.43 (2.72, 4.33) | 2.77 (2.17, 3.51) | <0.0001 |
Metformin | 172,813 | 3.30 | 0.66 (0.54, 0.79) | 0.80 (0.50, 1.39) | 0.0234 |
Pioglitazone | 4678 | 3.63 | 0.70 (0.42, 1.16) | 0.84 (0.50, 1.39) | 0.5007 |
Rosiglitazone | 504 | 3.96 | 0.81 (0.20, 3.23) | 0.92 (0.23, 3.63) | 0.9037 |
Heart failure | |||||
Antidiabetic drug (ref. = DPP4i) | 28,508 | 15.92 | – | – | – |
No antidiabetic drug | 101,166 | 25.23 | 1.50 (1.30, 1.71) | 1.28 (1.11, 1.47) | 0.0004 |
Sulfonylureas | 110,618 | 11.78 | 0.71 (0.62, 0.81) | 0.86 (0.74, 1.08) | 0.0322 |
Acarbose | 22,800 | 19.82 | 1.21 (1.03, 1.42) | 1.08 (0.92, 1.26) | 0.3227 |
Meglitinides | 13,103 | 48.23 | 2.91 (2.48, 3.40) | 1.85 (1.58, 2.16) | <0.0001 |
Insulin | 9632 | 92.80 | 5.67 (4.87, 6.58) | 3.71 (3.14, 4.37) | <0.0001 |
Metformin | 172,813 | 8.51 | 0.51 (0.44, 0.59) | 0.66 (0.57, 0.75) | <0.0001 |
Pioglitazone | 4678 | 9.40 | 0.57 (0.39, 0.80) | 0.76 (0.53, 1.07) | 0.1229 |
Rosiglitazone | 504 | 7.92 | 0.42 (0.15, 1.13) | 0.53 (0.19, 1.46) | 0.2226 |
Hypoglycemia | |||||
Antidiabetic drug (ref. = DPP4i) | 28,508 | 5.82 | – | – | – |
No antidiabetic drug | 101,166 | 5.23 | 0.83 (0.67, 1.00) | 0.76 (0.62, 0.92) | 0.0053 |
Sulfonylureas | 110,618 | 6.21 | 1.00 (0.84, 1.19) | 1.08 (0.91, 1.29) | 0.3621 |
Acarbose | 22,800 | 5.83 | 0.96 (0.77, 1.19) | 0.90 (0.72, 1.11) | 0.3402 |
Meglitinides | 13,103 | 18.16 | 2.91 (2.35, 3.59) | 2.09 (1.68, 2.58) | <0.0001 |
Insulin | 9632 | 39.44 | 6.41 (5.24, 7.84) | 4.55 (3.67, 5.64) | <0.0001 |
Metformin | 172,813 | 2.69 | 0.43 (0.35, 0.52) | 0.50 (0.41, 0.60) | <0.0001 |
Pioglitazone | 4678 | 5.77 | 0.93 (0.62, 1.40) | 1.07 (0.71, 1.60) | 0.7471 |
Rosiglitazone | 504 | 11.88 | 1.50 (0.66, 3.37) | 1.58 (0.70, 3.55) | 0.2679 |